Last reviewed · How we verify
Bismuth-based susceptibility-guided treatment
Bismuth-based susceptibility-guided treatment uses antimicrobial susceptibility testing to direct personalized bismuth-containing regimens for Helicobacter pylori eradication.
Bismuth-based susceptibility-guided treatment uses antimicrobial susceptibility testing to direct personalized bismuth-containing regimens for Helicobacter pylori eradication. Used for Helicobacter pylori infection (susceptibility-guided eradication).
At a glance
| Generic name | Bismuth-based susceptibility-guided treatment |
|---|---|
| Sponsor | National Cheng-Kung University Hospital |
| Drug class | Antimicrobial combination therapy (bismuth-based) |
| Target | Helicobacter pylori cell wall and bacterial proteins |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
This approach involves culturing H. pylori from patient samples and performing susceptibility testing to determine which antimicrobial agents the specific bacterial strain is sensitive to, then tailoring a bismuth-based triple or quadruple therapy accordingly. Bismuth compounds work synergistically with antibiotics to disrupt bacterial cell walls and reduce antibiotic resistance. This personalized, susceptibility-guided strategy aims to improve eradication rates compared to empirical standard regimens.
Approved indications
- Helicobacter pylori infection (susceptibility-guided eradication)
Common side effects
- Nausea
- Abdominal discomfort
- Diarrhea
- Metallic taste
- Black stool (bismuth-related)
Key clinical trials
- Fecal Molecular Susceptibility-guided Hp First-line Therapy (PHASE4)
- Fecal Molecular Susceptibility-guided Hp Rescue Therapy (PHASE4)
- Efficacies of Susceptibility-guided vs Empiric Therapy for Rescue Treatment of Helicobacter Pylori Infection (PHASE4)
- Susceptibility Testing Guided Versus Empirical Therapy for Refractory H. Pylori Infection (PHASE4)
- Efficacy of Vonoprazan-based Rescue Therapy for H. Pylori Eradication (NA)
- Comparison of Keverprazan Hydrochloride-Amoxicillin Dual Therapy and Susceptibility-Guided Quadruple Therapy for Helicobacter Pylori Rescue Treatment (PHASE3)
- Efficacy of a 14-Day Bismuth-Containing Quadruple Therapy Guided by Drug Susceptibility Testing in Patients with Extremely Refractory Helicobacter Pylori Infection: an Exploratory Study
- Susceptibility-guided Bismuth Quadruple Therapy for Multiple-resistant Helicobacter Pylori Strains (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: